|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,934.80 INR | -1.75% |
|
-4.02% | -4.93% |
| Feb. 02 | Glenmark Pharmaceuticals Posts Higher Profit in Fiscal Q3 | MT |
| Feb. 02 | Glenmark Pharmaceuticals Limited, Q3 2026 Earnings Call, Feb 02, 2026 |
| Capitalization | 546B 6.03B 5.1B 4.68B 4.44B 8.25B 8.59B 54.32B 21.5B 263B 22.61B 22.15B 951B | P/E ratio 2026 * |
30.5x | P/E ratio 2027 * | 23.7x |
|---|---|---|---|---|---|
| Enterprise value | 507B 5.6B 4.73B 4.34B 4.12B 7.66B 7.98B 50.41B 19.95B 244B 20.98B 20.55B 882B | EV / Sales 2026 * |
3.29x | EV / Sales 2027 * | 3.07x |
| Free-Float |
49.4% | Yield 2026 * |
0.15% | Yield 2027 * | 0.17% |
Last Transcript: Glenmark Pharmaceuticals Limited
| 1 day | -1.75% | ||
| 1 week | -4.02% | ||
| Current month | -4.02% | ||
| 1 month | -8.44% | ||
| 3 months | +6.81% | ||
| 6 months | -6.21% | ||
| Current year | -4.93% |
| 1 week | 1,842 |  | 2,006.6 |
| 1 month | 1,842 | | 2,079 |
| Current year | 1,842 | | 2,147.5 |
| 1 year | 1,275.5 | | 2,284.8 |
| 3 years | 387.65 | | 2,284.8 |
| 5 years | 348.5 | | 2,284.8 |
| 10 years | 161.65 | | 2,284.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 1999-12-31 | |
Indrajit Bose
PSD | President | - | 2023-09-14 |
Ulhas Dhuppad
PSD | President | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Cherylann Pinto
BRD | Director/Board Member | 58 | - |
| Chairman | 56 | 2011-05-11 | |
| Director/Board Member | 85 | 2009-08-13 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.75% | -4.02% | +25.62% | +393.01% | 6.03B | |
| -0.44% | +6.26% | -3.13% | +68.43% | 44.89B | |
| -1.46% | +1.11% | +17.89% | +128.57% | 31.43B | |
| -0.25% | +0.45% | -9.66% | +28.96% | 11.86B | |
| -1.86% | +0.32% | -10.66% | +85.24% | 9.86B | |
| -0.86% | +0.43% | +40.43% | +124.27% | 8.31B | |
| +0.70% | +4.06% | +148.76% | +839.85% | 7.95B | |
| -0.80% | +0.87% | +58.79% | +26.49% | 7.6B | |
| +0.81% | +7.90% | +61.65% | -12.13% | 7.44B | |
| -.--% | +0.14% | - | - | 6.79B | |
| Average | -0.59% | +2.45% | +36.63% | +186.97% | 14.22B | |
| Weighted average by Cap. | -0.70% | +3.21% | +20.54% | +136.55% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 154B 1.7B 1.44B 1.32B 1.25B 2.33B 2.43B 15.34B 6.07B 74.15B 6.39B 6.26B 269B | 163B 1.8B 1.52B 1.39B 1.32B 2.46B 2.56B 16.18B 6.4B 78.19B 6.73B 6.6B 283B |
| Net income | 19.59B 216M 183M 168M 159M 296M 308M 1.95B 771M 9.42B 811M 795M 34.11B | 23.08B 255M 216M 198M 188M 349M 363M 2.3B 909M 11.1B 956M 936M 40.19B |
| Net Debt | -39.29B -434M -367M -337M -319M -594M -618M -3.91B -1.55B -18.89B -1.63B -1.59B -68.42B | -47.03B -519M -439M -403M -382M -710M -740M -4.68B -1.85B -22.61B -1.95B -1.91B -81.89B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-02-06 | 1,934.80 ₹ | -1.75% | 490,999 |
| 26-02-05 | 1,969.30 ₹ | +0.51% | 401,353 |
| 26-02-04 | 1,959.30 ₹ | +0.26% | 388,216 |
| 26-02-03 | 1,954.20 ₹ | +1.76% | 535,670 |
| 26-02-02 | 1,920.40 ₹ | -1.01% | 1,487,788 |
Delayed Quote NSE India S.E., February 06, 2026 at 06:05 am EST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GLENMARK Stock
Select your edition
All financial news and data tailored to specific country editions
